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LEarly treatment of aortic stenosis will prevent poor outcomes and save
thousands of livesThierry-Pierre Carrel, MD,a Walter Dembitsky, MD,b Gilles Dreyfus, MD,c Gerard Champsaur, MD,d
Ghislaine Deklunder, MD, PhD,e Willem Flameng, MD, PhD,f Reiner K€orfer, MD,g Didier Lapeyre, MD,h
Bas de Mol, MD,i and Bart Meuris, MDfIn 2005, approximately 5 million adults in the United States
were diagnosed with aortic valve disease. In individuals
aged 65 years and older the prevalence increased dramati-
cally from 8% in people aged 65 to 79 years to 16% for
those aged 80 to 84 years. Valve replacement most often
is delayed as well as largely underused (<10%) for these in-
dividuals.1 The development of symptoms has been the pri-
mary driver for surgical intervention. The undisputed
paradigm of the past 4 decades is that clinical observation
was appropriate for treating patients with aortic stenosis.
The Current American College of Cardiology/American
Heart Association guidelines (2008) recommend surgery
for asymptomatic patients only as a class IIb indication.2
Recent clinical evidence challenges this old strategy.
Since the efficacy of targeted medical therapies to slow
down aortic stenosis progression was invalidated by several
randomized clinical trials (unbroken progression of6 mm
Hg mean gradient per year, 0.1 cm2/y valve area reduction),
the risk of watchful waiting strategy now appears greater
than the risk of surgery.3 Many studies have shown that
long-term results of aortic valve replacement vary consider-
ably depending on the timing of surgery. When surgery is
performed early, patients can live for 15 years and more
with a high quality of life, and at a low cost. These patients
can be considered cured because their life expectancy is
equivalent to that of individuals of the same age in the gen-
eral population.3 In contrast, when patients are treated after
the onset of symptoms, life expectancy is greatly reduced
regardless of age, and is much more costly.
We therefore question the value of the options offered to
‘‘high-risk’’ and inoperable patients because treatment at
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4 The Journal of Thoracic and Cardiovascular Surgerstatistical study in the United States based on Society of
Thoracic Surgeons databases recently published in the jour-
nal Circulation reported that the median survival time in
more than 7000 patients with an STS risk score of 10%
or greater treated by conventional surgery was only 2.6
years. In contrast, 100,000 patients between the ages of
65 and 80 years presenting with an STS risk score of less
than 4% lived for more than 10 years after aortic valve re-
placement with a high quality of life. After age 80, even
with concomitant coronary surgery, the median survival pe-
riod for these patients still exceeds 7 years.4
Although patients with severe aortic stenosis may experi-
ence angina or syncope, their predominant clinical manifes-
tations are insidious heart failure symptoms.Overt symptoms
appear late in the progression of the disease. Most impor-
tantly, increasing functional, radiologic, echocardiographic,
pathologic, and biological efficient screening tools now
point to a clear advantage for valvular replacement per-
formed early for a favorable long-term outcome.5 Evidence
is accumulating that subclinical myocardial alterations prog-
ress rapidly, even when ventricular ejection fraction remains
normal. Increasing hypertrophy provokes interstitial fibro-
sis, which irreversibly degrades cardiac function. More
than half of asymptomatic patients present with often-
irreversible latent pulmonary hypertension, which reduces
life expectancy. The aortic valve calcium score has been
shown to be an independent predictor of event-free survival
in subjects with only moderate aortic stenosis. Guidelines
from the European Cardiology and Cardiac Surgery Socie-
ties, updated in September 2012, recommend surgery for
asymptomatic patients when exercise tests are positive,
which is often the case.6 The silent transition from ventric-
ular hypertrophy to heart failure denotes the tipping point
at which the left ventricle fails under increased pressure
afterload. This heralds the onset of symptoms, and a poor
prognosis.
The clinical benefit of prevention of irreversible myocar-
dial damage induced by critical aortic stenosis appears suf-
ficiently established to spare the need for randomized
prospective studies to compare the mortality rate of the
watchful waiting strategy with the mortality rate after pre-
emptive valvular replacement. Such complex studies would
be difficult to complete for obvious ethical reasons. In addi-
tion, randomization may pose methodologic problems be-
cause a significant number of observed asymptomatic
patients are likely to develop symptoms throughout they c July 2013
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Lstudy and cross-over to the therapeutic arm. Achieving
sufficient statistical significance would take many years.
Because patients at low risk can be considered cured
by surgery and because it is established that untreated
aortic stenosis ineluctably induces irreversible myocardial
damage, it is counterintuitive that long-term outcomes of
the wait-and-see strategy will be better than those of the
pre-emptive option.
Progress in diagnostics should finally end this old
dilemma and reverse the growing epidemic of end-stage
patients who become candidates for palliative procedures.
When pathology puts the vital prognosis at stake, preven-
tion is always the best therapy. This rule is well established
for cancer and most life-threatening diseases. Given the
high frequency, severe aortic stenosis (the next cardiac
epidemic) should be no exception. Therefore, greater atten-
tion should be given to the early detection of silent aortic
stenosis and to the timing of surgery using proven methods
and replacement valves. This action greatly would reduce
the number of patients defined as nonoperable or high risk.
After 10 years and more than an estimated 50,000 im-
plants worldwide, transcatheter valve therapy still remains
experimental. Procedure complexity, vascular complica-
tions, site calcification, paravalvular leaks, conduction dis-
turbances, and stroke are frequent barriers to safe and
efficient implementation. Because long-term risks and ben-
efits of this procedure remain largely unknown, there is no
reason to wait until this technology eventually is improved
to reconsider the prevailing watchful waiting paradigm
when well-established surgical procedures can have an im-
mediate and profound impact on patient longevity and qual-
ity of life. The large retrospective reviewmentioned earlier4
strongly suggests that systematic detection and early treat-
ment would save thousands of lives and allow for a substan-
tial cost savings.
The right timing for a surgical intervention is always
weighed against the risks of the procedure and theThe Journal of Thoracic andimplanted device. Our current commercial valves are still
based on designs, materials, and tissue-preservation
methods from the 1970s and 1980s. ‘‘In contrast to the pio-
neering years, courage and incentive towards a new devel-
opmental quantum leap have been mostly absent from
commercial product strategies.’’ Although transcatheter
valve procedures offer a palliative option for the elderly,
the needs of younger patients for an anticoagulant-
independent and durable-for-life heart valve substitute still
have not been met. If better valve substitutes were avail-
able, this would shift the balance further toward earlier
intervention and improved outcomes.
The authors wish to thank Rolland Siegel and Lawrence N.
Scotten, DiplT, for their generous assistance in the preparation
of this manuscript.
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